Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative disorder affecting the CNS during infancy. INCL is caused by mutations in the
Introduction
Infantile neuronal ceroid lipofuscinosis (INCL), or Batten disease, is an autosomal-recessive, lysosomal storage disease affecting the CNS (Kohlschütter et al., 1993; Hofmann et al., 1999) . Caused by a deficiency in palmitoyl protein thioesterase 1 (PPT1) (Vesa et al., 1995; Hofmann et al., 2001) , INCL patients are asymptomatic at birth and develop normally until they present with visual impairments, seizures, cognitive deficits, and motor dysfunction. Death occurs by 6 years (Santavuori et al., 1973; Santavuori et al., 1974) . Pathological findings include autofluorescent storage material, glial activation, brain atrophy, cortical thinning, neuronal loss, and demyelination (Haltia et al., 1973a,b) . A PPT1-deficient (PPT1 Ϫ/Ϫ ) mouse model was generated by disrupting the CLN1 gene ) and mimics the cellular pathology and functional deficits observed in INCL patients Griffey et al., 2004 Griffey et al., , 2005 Griffey et al., , 2006 Kielar et al., 2007; Macauley et al., 2009 ).
Previous studies demonstrated that localized regions of increased expression of an intermediate filament protein glial fibrillary acidic protein (GFAP) expression are the first pathological changes observed in the PPT1 Ϫ/Ϫ brains (Kielar et al., 2007; Macauley et al., 2009 ). These regions also suffer the greatest neuronal loss and atrophy as the disease progresses. We hypothesize that the upregulation of intermediate filament proteins in reactive astrocytes plays an active role in the pathogenesis of INCL.
The role of intermediate filament upregulation is an incompletely understood phenomenon in CNS disease (Kalman, 2004; Pekny and Nilsson, 2005; Sofroniew, 2005) . Although GFAP upregulation is a common indicator of reactive astrocytes, the relationship between increased intermediate filament protein expression (i.e., GFAP, vimentin, and nestin) during astrocyte hypertrophy and functional changes at the molecular level remains unclear. Given the elaborate set of functions associated with reactive astrocytes, we and others described astrocyte activation as both a gain and loss of function phenomenon resulting in favorable and deleterious effects to an injured CNS, based on data gathered from numerous transgenic mouse studies (Pekny and Nilsson, 2005; Sofroniew et al., 2009; Sofroniew and Vinters, 2010) . Mice deficient in astrocyte intermediate filament proteins, GFAP and vimentin (Vim), address the relationship between structural alterations and functional changes associated with astrocyte activation, and report both positive (e.g., axonal sprouting, synaptic regeneration, faster wound healing, decreased immune cell infiltration) and negative (e.g., disrupted glial scars, larger infarct volumes, increased cell death) outcomes when challenged (Pekny et al., 1995 Lane and Pekny, 2004 For the purposes of our studies, we used mice deficient in GFAP and Vimentin (GFAP Ϫ/Ϫ Vim Ϫ/Ϫ ) as a model of attenuated astrocyte activation. By crossing the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice with the PPT1 Ϫ/Ϫ mice, we were able to study the role of attenuated astrocyte activation in INCL. In the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains, the course of disease is exacerbated compared with PPT1 Ϫ/Ϫ mice. Mechanisms responsible for this accelerated phenotype include immune cell infiltration and cytokine upregulation. These data suggest that astrocyte activation plays a protective role in INCL.
Materials and Methods

GFAP
Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice. The individual GFAP Ϫ/Ϫ Vim Ϫ/Ϫ and PPT1 Ϫ/Ϫ mice were created as previously reported (Colucci-Guyon et al., 1994; Pekny et al., 1995 Pekny et al., , 1999 Eliasson et al., 1999; Gupta et al., 2001; Griffey et al., 2005) . The GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice were of a mixed C57BL/ 6/129SV/129Ola background, and the PPT1 Ϫ/Ϫ mice were of a congenic C57BL/6 background. The homozygous GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice were crossed with the homozygous PPT1 Ϫ/Ϫ mice for the first initial mating. The heterozygous progeny (GFAP ϩ/ Ϫ Vim ϩ/ Ϫ PPT1 ϩ/ Ϫ ) of the initial mating were backcrossed to the PPT1 Ϫ/Ϫ background for two additional generations, producing an 88% C57BL/6 background. Then, the heterozygous GFAP ϩ/ Ϫ Vim ϩ/ Ϫ PPT1 ϩ/ Ϫ offspring were intercrossed to ultimately generate all four groups (GFAP
, and WT). For the purposes of our studies, the mice were all generationally matched and maintained as four distinct homozygous lines. The only exception was that the silver degeneration staining was performed on PPT1 Ϫ/Ϫ and WT mice with a congenic C57BL/6 background. All mice were maintained at Washington University School of Medicine. Mouse genotypes were determined by PCR-based assays. Both male and female mice from each genotype were used in this study. Animals were housed under a 12 h light/dark cycle and were provided food and water ad libitum. All procedures were performed under an approved Institutional Animal Care and Use Committee protocol from Washington University School of Medicine.
Longevity. GFAP
, and WT mice (n ϭ 10 -18 mice per genotype) were used to assess lifespan. Mice from each group were allowed to age, unmanipulated, under the conditions described above. The end of life was signaled by either death or a predetermined moribund condition. Kaplan-Meier analysis was used to measure cumulative survival and determine differences ( p Ͻ 0.05) in lifespan.
Brain weights. The 3-, 5-, and 6-month-old
Ϫ/Ϫ , and WT mice (n ϭ 5-6 mice/ genotype/age) were killed via an overdose of euthasol, and the brains were harvested by a researcher blinded to both age and genotype. A razor blade was inserted coronally between the forebrain and olfactory bulbs to remove the olfactory bulbs from the remainder of the brain. Similarly, a coronal cut was made immediately posterior to the cerebellum to remove the medulla and spinal cord from the forebrain and cerebellum. Each brain was weighed. Differences in weights were analyzed with one-way ANOVAs followed by Bonferroni's correction post hoc tests.
Autofluorescent accumulation. Six-month-old GFAP Ϫ/Ϫ Vim
Ϫ/Ϫ , and WT mice (n ϭ 3 mice per group) were used to quantify autofluorescent accumulation in the somatosensory barrel field (S1BF) cortex using epifluorescent microscopy Kielar et al., 2007) . Briefly, mice were given an overdose of euthasol, and the brains were removed and fixed for 48 h in 4% PFA in phosphate buffer. Following fixation, the brains were cryoprotected in 30% sucrose, embedded in optimal cutting temperature compound (OCT; Sakura), and sectioned coronally on a freezing cryostat at 20 m thickness. Images from three serial sections through S1BF for each group were captured via a 20ϫ objective and FITC filter on a Nikon microscope with a SPOT camera attached. All variables associated with image capture, including exposure time, binning, and gain, were held constant for all groups. Using ImageJ software, threshold analysis was performed to determine which pixels contained autofluorescent accumulation in a given image. The percentage of pixels containing autofluorescent material was calculated for each image and reported as the area fraction. Three sets of area fraction measurements were captured for each of the three sections through S1BF in each of the four groups. The average for each group was calculated. Differences in autofluorescent accumulation were analyzed using a one-way ANOVA followed by Bonferroni's correction post hoc test.
Nissl staining. Nissl staining was performed on 6-month-old GFAP
Ϫ/Ϫ , and WT mice (n ϭ 3 mice per group). Briefly, mice were given a lethal injection of euthasol, the brains removed, fixed for 48 h in 4% PFA in phosphate buffer, cryoprotected in 30% sucrose, embedded in OCT, and sectioned coronally on a freezing cryostat at 20 m thickness. Sections throughout the primary visual cortex (V1) were mounted on glass slides, placed on a warming plate for 1 h and allowed to thoroughly dry overnight at room temperature. Sections were briefly rinsed in distilled H 2 O (dH 2 O), incubated in 0.5% cresyl violet for 2 min, and rinsed with dH 2 O. The sections were then dehydrated via a series of alcohols and xylenes, and coverslipped.
Cortical thickness. Cortical thickness measurements were performed on Nissl-stained tissue from GFAP
Ϫ/Ϫ and WT brains (n ϭ 3 brains per group). Images throughout V1 were captured at 10ϫ magnification using an Olympus BX41 microscope and Olympus DP 20 camera. Cortical thickness measurements were made by an observer blinded to genotype from the boundary of the white matter to the pial surface for each brain, as delineated by Paxinos and Franklin (1997) and as previously described Kielar et al., 2007) . A series of 10 individual measurements was made for each of three sections for each mouse (n ϭ 3 mice per group). For each mouse, the mean cortical thickness measurement for each section was calculated, and statistical significance was performed by a one-way ANOVA followed by Bonferroni's correction post hoc test.
de Olmos cupric-silver staining. Three-, 5-, and 6-month-old GFAP
Ϫ/Ϫ , and WT mice (n ϭ 2 per time point) were processed for de Olmos silver staining. Briefly, the mice were deeply anesthetized with euthasol and transcardially perfused with 4% paraformaldehyde in sodium cacodylate buffer. The brains were removed and postfixed for 48 h. Each brain was embedded in a gelatinbased matrix (Switzer, 2000) , and serial coronal sections (35 m) were made on a freezing microtome by Neuroscience Associates. Neuronal degeneration was visualized by staining with a modified de Olmos cupric-silver method (DeOlmos and Ingram, 1971; Switzer, 2000) . A matrix of brains at identical levels in the coronal plane was stained simultaneously.
Blood-brain barrier permeability. Blood-brain barrier (BBB) integrity was assessed in 5-month-old WT and GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ (n ϭ 4 mice per group) using an Evan's blue (EB) assay (Belayev et al., 1996; Young et al., 2004) . PPT1-deficient mice receiving a middle cerebral artery occlusion (MCAO) served as a positive control. Mice were injected with 2% Evan's blue in saline via a tail vein injection (4 l/g body weight). After 30 min, the mice were transcardially perfused with PBS until both the perfusate and liver were clear of blood (ϳ1-2 min). The brains were removed, bisected sagittally, and weighed. One hemisphere was placed in 500 l of 50% TCA solution and homogenized for 1 min. Following centrifugation, the dye was extracted and diluted 1:3 in EtOH. To determine the concentration of Evan's blue dye in samples, the fluorescence of each sample was determined by a fluorescent spectrophotometer (F-2000, Hitachi; excitation of 620 nm and emission at 680 nm), and the concentration was calculated based on external standards (100 -500 ng/ ml) per gram of tissue. A one-way ANOVA was performed to determine statistical significance at the p Ͻ 0.05 level, with Tukey's multiplecomparison's post hoc test.
Middle cerebral artery occlusion. Middle cerebral artery (MCA) occlusion was achieved using a nylon suture for 60 min as described previously (Belayev et al., 1996) . Using an operating microscope, the left external carotid artery (ECA) was exposed and loosely ligated with a 5-0 silk suture through a midline neck incision in anesthetized mice. The distal stump of the ECA and the branches to the proximal stump were electrocoagulated. A 12 mm 6 -0 surgical monofilament nylon suture was introduced into the ECA stump, advanced 9 -10 mm from the bifurcation of the common carotid artery into the circle of Willis to occlude the ostium of the MCA to cause a 20% decrease in laser Doppler signal. The 6 -0 silk suture ligating the proximal ECA was tightened to prevent bleeding and immobilize the intraluminal suture inserted into the MCA. Mice were transferred to an incubator (32°C) and allowed to recover from anesthesia. After 60 min, ischemia will be terminated by removal of the intraluminal suture. Restoration of blood flow through the internal carotid artery following removal of the intraluminal suture will be confirmed directly under an operating microscope and more distally by laser Doppler (Miller et al., 2001; Gidday et al., 2005) .
Immunohistochemistry. Six-month-old
Ϫ/Ϫ , and WT mice were killed via an overdose of euthasol and transcardially perfused with PBS until the liver was clear of blood. The brains were removed and fixed in 4% paraformaldehyde in phosphate buffer for 48 h, were cryoprotected with 30% sucrose in Trisbuffered saline (TBS), and embedded in OCT. Brains were sectioned in the coronal plane throughout the rostral-caudal axis using a freezing cryostat. Adjacent, free-floating sections were incubated with the following antibodies: rabbit anti-GFAP (1:500; Immunostar); rat anti-CD68 (1:500; AbD, Serotec); rat anti-CD31 [1:50; platelet endothelial cell adhesion molecule-1 (PECAM), BD PharMingen); rat anti-CD45 (1:50; BD PharMingen); rabbit anti-CD3 (1:200; Laboratory Vision); and rabbit anti-aquaporin 4 (AQP4; 1:1000; Millipore Bioscience Research Reagents). Briefly, sections were washed in TBS, incubated in 1% H 2 O 2 (Sigma) to quench endogenous peroxidase activity, and rinsed thoroughly in TBS. The tissue was blocked for 1 h in 10% normal goat serum (NGS; Sigma) and 0.25% Triton X-100 in TBS. Sections were incubated overnight at 4°C with primary antibodies in 5% NGS and 0.2% Triton X-100 in TBS. The following day the sections were rinsed in TBS and incubated with secondary antibodies (1:500 -1000, Vector Laboratories; or 1:500, Invitrogen) in 10% NGS and 0.1% Triton X-100 in TBS for 75 min. The tissue was rinsed with TBS and then incubated with a peroxidase-conjugated avidin-biotin complex (1:100; Vectastain Elite ABC kit, Vector Laboratories) for 1 h at room temperature. Antibody immunoreactivity was visualized with 3Ј-3Ј diaminobenzidine and H 2 O 2 (DAB kit, Vector Laboratories) in TBS. Sections were dehydrated and coverslipped.
Quantitation for CD68-positive cells was performed in the S1BF cortex of 6-month-old WT, GFAP Ϫ/Ϫ Vim Ϫ/Ϫ , PPT1 Ϫ/Ϫ , and GFAP
Images through the S1BF were captured using a 20ϫ objective, Olympus BX41 microscope and Olympus DP 20 camera. All variables associated with image capture were held constant. Using ImageJ software, images were converted to 8-bit grayscale, and threshold analysis was used to identify CD68-positive cell bodies within the cortex. Cell counts were performed on three sets of images taken per section, on three sections total from three different brains per each genotype (n ϭ 4). Statistical significance was calculated using a one-way ANOVA followed by Tukey's post hoc test.
To quantify CD3-positive cells, images were captured in the S1BF cortex of 6-month-old WT,
Images through the S1BF were captured using a 20ϫ objective, Olympus BX41 microscope and Olympus DP 20 camera, where all variables associated with image capture were held constant. Manual cell counts were performed on three sets of images taken per section, on three sections total from three different brains per each of four genotypes. Statistical significance was calculated using a one-way ANOVA followed by Tukey's post hoc test.
Cytokine assays. To quantify the concentration of chemokines and cytokines within the brain, a 14-biomarker Multi-Analyte Profile was generated for 1-, 3-, and 6-month-old , and tumor necrosis factor-␣ (TNF-␣). Briefly, mice were transcardially perfused with PBS, and the brains were homogenized in a solution consisting of 10 mM Tris, 150 mM NaCl, 1 mM dithiothreitol, 0.2% Triton, and 20 l/ml protease inhibitor cocktail (Sigma). The supernatant from brain homogenates was diluted to obtain a protein target concentration of 0.5-1.0 mg/ml and stored at Ϫ70°C. Cytokine concentrations were quantified according to standard protocols at MYRIAD RBM. A one-way ANOVA followed by Bonferroni's post hoc tests was used to determine significant changes in cytokine levels at each time point.
Results
GFAP upregulation in the PPT1
؊/؊ mouse GFAP upregulation, which precedes neuronal loss (Kielar et al., 2007; Macauley et al., 2009) , is one of the first histological changes seen in the PPT1 Ϫ/Ϫ brain (Fig. 1a) . Focal areas of GFAP upregulation occur in the PPT1 Ϫ/Ϫ astrocytes beginning at 3 months of age (Fig. 1a, black arrows) . Specifically, there is a notable increase in GFAP immunostaining throughout multiple cortical, thalamic, and cerebellar regions in PPT1 Ϫ/Ϫ mice. As the mice age, there is a change in the intensity and distribution of GFAP immunostaining throughout these regions as well as other areas in the brain (blue arrows), including the hippocampus, striatum, and brainstem.
At higher magnification, the GFAP-positive processes of immunostained astrocytes at 3 month of age appeared to surround blood vessels (Fig. 1a, black arrows) . However, as the mice age, there appeared to be changes in GFAP immunoreactivity within reactive astrocytes. By 5-7 months of age, the distribution of GFAP immunostaining in individual cells appeared more intense and revealed more "star-shaped" protoplasmic astrocytes with hypertrophied processes.
Another molecule often altered in reactive astrocytes concurrent with GFAP upregulation is AQP4, a prominent water channel localized to astrocytic endfeet. We performed double-labeling experiments for AQP4 and the endothelial marker PECAM (CD31), in the PPT1 Ϫ/Ϫ and WT brains at 7 months of age (Fig.  1b) . In the WT brains, PECAM (CD31) immunostaining demarcated the vascular bed. AQP4 immunostaining in WT brains followed the outline of the vasculature, consistent with localization to the astrocytic endfeet. This pattern of staining was disrupted in the PPT1 Ϫ/Ϫ brains. Moreover, immunostaining for AQP4 resulted in a more diffuse pattern of staining where the localization to astrocytic endfeet appeared to be less discrete. mice developed normally with no difference in brain weights observed at 3 months of age (Fig. 3a) . However, by 5 months, brain atrophy was apparent in both the GFAP
Accelerated INCL phenotype in GFAP
and PPT1 Ϫ/Ϫ mice (Fig. 3b) . At 6 months, there was a decrease in the brain weights of the GFAP
, and PPT1 Ϫ/Ϫ mice ( p Ͻ 0.001) compared with WT mice (Fig. 3c) and PPT1 Ϫ/Ϫ mice appeared atrophied compared with WT brains (Fig. 3d) . Therefore, we measured cortical thickness in V1 at 6 months of age in the GFAP 
Ϫ/Ϫ , and WT brains (Fig. 3f ) . There was an increase ( p Ͻ 0.001) in autofluorescent accumulation in both the GFAP 
Increased neurodegeneration in the GFAP
Since neuronal loss is a hallmark of INCL, de Olmos cupric-silver staining was performed to assess the extent of neurodegeneration present in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains (Fig. 4) . We compared the severity of pathology in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ Figure 1 . Reactive astrocytes in the PPT Ϫ/Ϫ brains. a, Focal regions of GFAP upregulation occur in the PPT1 Ϫ/Ϫ brain. GFAP upregulation is present in the thalamus, cortex, and cerebellum beginning at 3 months (black arrows). By 5-7 months, the intensity and distribution of GFAP immunostaining increases (blue arrows). At high magnification in the V1, the first GFAP-positive astrocytes observed at 3 months are associated with the vasculature (black arrows). As the PPT1 Ϫ/Ϫ mice age, more star-shaped protoplasmic astrocytes demonstrate GFAP immunoreactivity. Staining was absent in the 7-month-old WT brains. b, Immunostaining for PECAM and AQP4 in WT and PPT1 Ϫ/Ϫ brains. PECAM immunostaining outlines the blood vessels in the WT V1, which is closely associated with the AQP4 labeling of astrocytic endfeet. The pattern of AQP4 staining was disrupted in the PPT1 Ϫ/Ϫ mice. The AQP4 staining was not limited to PECAM-positive vasculature in the PPT1 Ϫ/Ϫ mice. 
Figure 2. Lifespan of the GFAP
Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice. The GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice died earlier than the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ , PPT1 Ϫ/Ϫ ,
PPT1
Ϫ/Ϫ mice to the PPT1 Ϫ/Ϫ , GFAP Ϫ/Ϫ Vim Ϫ/Ϫ , and WT mice at 5 months of age (Fig. 4a,c) . Little or no silver staining was present in either the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ or WT brains. Conversely, the PPT1 Ϫ/Ϫ brains showed blackened cellular profiles and axonal projections throughout the neuraxis, seen here in the hippocampus, thalamus, and cortex (Fig. 4a) . The same pattern of staining was present in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice, but the staining was more intense when compared with the PPT1 Ϫ/Ϫ mice. Higher-magnification images showed degenerating neurons within the cortex, thalamus, hippocampus, and cerebellum of the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains at 5 months of age (Fig. 4b) . In addition to the regional distribution of neurodegeneration, we also investigated the temporal progression of disease in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice at 3, 5, and 6 months of age (Fig. 4c) . As the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice age, there is an increase in silver staining throughout the cortex, corpus callosum, hippocampus, and thalamus. Although silver staining is present in the cortex and thalamus at 3 months of age, the hippocampus is relatively spared. As the mice age, darkly stained profiles are apparent in the hippocampus as well as the cortex. Similarly, staining in the corpus callosum increases in intensity by 5 months of age. By 6 months, the intensity of staining is more intense than in a 7-month-old PPT1 Ϫ/Ϫ brain (Fig. 4c) . In fact, the intensity of staining in the 7-month-old PPT1 Ϫ/Ϫ brain is comparable to a 5-month-old GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brain.
Increased immune cell infiltration in the GFAP
brains stained with H&E displayed a small cell infiltrate not present in the PPT1 Ϫ/Ϫ , GFAP Ϫ/Ϫ Vim Ϫ/Ϫ , or WT brains (data not shown). Hypothesizing the small cell infiltrate was composed of blood-derived leukocytes, CD45 immunostaining, a panleukocyte marker, was performed in the GFAP
, and WT brains (Fig.  5a ). At 5 months of age, the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice appeared to have more CD45-positive cells throughout the brains compared with PPT1 Ϫ/Ϫ and controls (Fig. 5a) . No increase in CD45-positive staining was seen in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice compared with WT animals (data not shown).
At higher magnification, it was clear that the CD45-positive cells within the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains were morphologically diverse ( Fig. 5b-d,  arrows) . To ascertain what CD45 populations were present in the brain parenchyma, lineage-specific markers were used to identify two distinct populations. First, anti-CD3 labeling identified T cells throughout the neuraxis in both the GFAP
PPT1
Ϫ/Ϫ and PPT1 Ϫ/Ϫ brains but not in the WT or GFAP Ϫ/Ϫ Vim Ϫ/Ϫ brains (Fig. 5e ). There was an increase in the number of CD3 (Fig. 5g) . There was no difference in the number of CD3
and PPT1 Ϫ/Ϫ brains. Interestingly, the greatest increase in immune cells was observed in the monocyte population in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains (Fig. 5f,h ). Using an anti-CD68 antibody to identify microglia and macrophages, a large population of CD68-positive cells was observed in both the PPT1 Ϫ/Ϫ and GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains (Fig. 5f ). There was a 24% increase in the number of CD68-positive profiles within the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains compared with the PPT1 Ϫ/Ϫ (Fig. 5h) ( p Ͻ 0.001). Neither the WT nor GFAP Ϫ/Ϫ Vim Ϫ/Ϫ brains had an appreciable monocyte population within the brain.
Blood-brain barrier integrity of the GFAP
؊/؊ Vim ؊/؊ PPT1 ؊/؊ mice To detect possible perturbations in the BBB, a quantitative EB assay was used (Fig. 6) 
PPT1
Ϫ/Ϫ mice compared with PPT1 Ϫ/Ϫ , GFAP Ϫ/Ϫ Vim Ϫ/Ϫ , and WT mice (n ϭ 3 per group). Only significant differences as determined by one-way ANOVA followed by Bonferroni's post hoc tests were highlighted on the graph: *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001.
Elevated cytokine levels in the GFAP
؊/؊ Vim ؊/؊
PPT1
؊/؊ mice A panel of 14 chemokines/cytokines was simultaneously evaluated in 1-, 3-, and 6-month-old GFAP
, and WT brains. The cytokines can grossly be divided into the following three groups based on function: (1) generalized proinflammatory molecules (Fig. 7a,d,g ); (2) lymphocyte and/or monocyte activators (Fig. 7b,e,h) ; or (3) monocyte activators (Fig. 7c,f,i) . At 1 month, there were increased concentrations of two cytokines known to act on lymphocytes and/or monocytes, RAN-TES and oncostatin-M, in the GFAP
Ϫ/Ϫ brains, but no changes were observed in either the GFAP
Ϫ/Ϫ brains compared with WT ( Fig. 7a-c) . By 3 months of age, 12 analytes displayed increased expression in either the GFAP
Ϫ/Ϫ or PPT1 Ϫ/Ϫ mice compared with WT ( Fig. 7d-f ). (Fig. 7g-i) . Interestingly, the concentrations of several cytokines in the PPT1 Ϫ/Ϫ brain known to activate and recruit monocytes (Fig. 7i) , including IP-10, MCP-1, MCP-3, and MCP-5, were higher than that of aged matched GFAP
Discussion
The first histopathological change observed in the PPT1
mouse is the upregulation of the intermediate filament protein, GFAP, in reactive astrocytes. GFAP upregulation was present as early as 3 months of age in the thalamus, cortex, and cerebellum 
At 5 months of age, there was no staining within the WT or GFAP Ϫ/Ϫ Vim Ϫ/Ϫ brains. Neurodegeneration in the PPT1 Ϫ/Ϫ brain (n ϭ 2) was localized to the corpus callosum, hippocampus, and thalamus (arrows). In the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brain (n ϭ 2), staining in these regions appeared more intense, suggesting an accelerated disease course (n ϭ 2 per group). Scale bar, 300 m. b, Representative images from the cortex, thalamus, hippocampus, and cerebellum of 5-month-old GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice. Darkly stained cell bodies were present in the cortex (scale bar, 50 m) and CA1 field of the hippocampus (scale bar, 50 m), while degenerating axons are present in the thalamus (scale bar, 100 m) and cerebellar white matter tracts (scale bar, 50 m). c, Time course of silver degeneration staining in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice. As the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice age, there is an increase in silver staining throughout the cortex, corpus callosum, hippocampus, and thalamus. Interestingly, the level of staining in a 7-month-old PPT1 Ϫ/Ϫ brain is comparable to that observed in a 5-month-old GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brain and is far less than that of a 6-month-old GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brain. Scale bar, 300 m.
of PPT1 Ϫ/Ϫ mice. Subsequent to this marker of early-stage astrocyte activation, there was significant neuronal loss in the same regions (Kielar et al., 2007; Macauley et al., 2009) . Therefore, we hypothesized that astrocyte activation plays a role in the pathogenesis of INCL. If so, are reactive astrocytes beneficial or detrimental to the INCL brain?
In the absence of the intermediate filament proteins, GFAP and vimentin, the time course of disease was accelerated in the
mice displayed either an earlier onset of the disease (i.e., premature death and brain atrophy) or an increased severity of disease at a particular time point (i.e., cortical thinning, autofluorescence, neurodegeneration, and immune cell infiltration). These data suggest that intermediate filament upregulation associated with reactive astrocytes, is a protective process in INCL. Although reactive astrocytes are responsible for both positive and negative outcomes in the CNS, our results are consistent with previous findings that use transgenic models to either ablate scar-forming astrocytes or knock out specific molecules associated with reactive astrocytes. Ablating scar-forming astrocytes (Bush et al., 1998 (Bush et al., , 1999 in models of experimental autoimmune encephalo- 
PPT1
Ϫ/Ϫ compared with WT mice (n ϭ 4 per group). There was an increase in Evan's blue concentration following an MCAO. Statistical differences were assessed using a one-way ANOVA followed by a Tukey's post hoc test (*p Ͻ 0.05). myelitis (Voskuhl et al., 2009) , traumatic brain injury (Myer et al., 2006) , and spinal cord injury (Faulkner et al., 2004) resulted in increased tissue damage, greater infarct size, increased neurodegeneration, increased demyelination, and exacerbated neuroinflammation. Likewise, mice lacking GFAP and vimentin that were given ischemic injury (Li et al., 2008) , traumatic brain injury Wilhelmsson et al., 2004) , or spinal cord lesions had increased post-traumatic recovery time, clinical outcomes, and lesion size. Although each transgenic model has a unique set of limitations for studying reactive astrocytes (i.e., neither GFAP nor vimentin is solely expressed by astrocytes), the cumulative results from these studies help further our understanding of the cellular, molecular, and functional changes associated with astrocyte activation.
In an effort to investigate the underlying mechanism causing the accelerated phenotype in GFAP Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains were morphologically diverse, containing both a large monocyte (CD68 ϩ ) and T-cell (CD3 ϩ ) population. We hypothesize that early activation of microglia and infiltration of both macrophages and T cells were contributing to the accelerated disease course observed in the GFAP
Although the vimentin deficiency interferes with leukocyte and monocyte adhesion and extravasation (Nieminen et al., 2006) , the addition of the PPT1 and GFAP mutations appeared to counteract this effect and allow increased cell entry into the CNS.
To examine the possible mechanisms for immune cell entry into the CNS, our work focused on the blood-brain barrier. Interestingly, the astrocytes that first display an increase in GFAP immunoreactivity appear to be in intimate contact with the vasculature. Furthermore, PPT1 Ϫ/Ϫ mice appear to have aberrant PECAM and AQP4 immunostaining, suggesting alterations in the gliovascular unit. Thus, the ability of a large EB-albumin complex to enter the brain parenchyma was used to investigate BBB integrity. No gross perturbation of the BBB was appreciable in either the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ or PPT1 Ϫ/Ϫ mice, findings similar to those previously reported in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice (Pekny and Wilhelmsson, 2006) . Given that the BBB is both a physical and molecular barrier, the molecular signals expressed in the CNS responsible for microglial activation and monocyte and leukocyte recruitment were investigated. At 1 month, there were elevations in two cytokines in the GFAP 
Ϫ/Ϫ brains. Both of these proinflammatory molecules are often elevated in the CNS in response to acute injury or chronic disease. They are responsible for the activation and regulation of both resident (i.e., astrocytes and microglia) and infiltrating (i.e., T cells and macrophages) immune cells. IFN-␥ is known to be a potent inducer of class II MHC expression in astrocytes, which is subsequently responsible for the activation of both T cells and macrophages. Furthermore, production of IFN-␥ can damage the BBB due to cytotoxic effects on endothelial cells (Chavarria and Alcocer-Varela, 2004) . The elevation of both TNF-␣ and IFN-␥ in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains, but not in the PPT1 Ϫ/Ϫ brains, suggests that attenuated astrocyte activation exacerbates neuroinflammation in the CNS. Furthermore, it suggests that this is a widespread phenomenon affecting a variety of cell types in the CNS, namely astrocytes, microglia/macrophages, and infiltrating lymphocytes.
The second set of elevated cytokines in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains demonstrated the largest fold change (i.e., a 6 -20-fold change). In all cases, these cytokines (i.e., IP-10, MIP1␤, MIP-2, MCP-1, MCP-3, and MCP-5) are responsible for the activation and recruitment of microglia and monocytes within the CNS. Not surprisingly, this upregulation correlated with an increase in the number of CD68-positive monocytes found within the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains. These molecules are not only responsible for the recruitment and activation of monocytes, but also cause an increase in cytokine expression within these cells, propagating the neuroinflammatory process.
The final group of cytokines (i.e., oncostatin-M, lymphotactin, GM-CSF, and RANTES) is responsible for the recruitment and activation of T cells in addition to monocytes. Again, these data correlate with immunostaining of the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains that demonstrate the presence of CD3-positive T cells within the CNS. One molecule, oncostatin-M, is also expressed by endothelial cells and facilitates leukocyte adhesion and rolling necessary for extravasation of cells across the blood-brain barrier. Oncostatin-M, along with RANTES, were the only two cytokines upregulated in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ brains at 1 month. Thus, we demonstrate molecular and cellular changes, which could increase inflammation within the CNS in the presence of attenuated astrogliosis. We believe this proinflammatory cascade is one explanation for the accelerated neurodegeneration and premature death of GFAP in PPT1 Ϫ/Ϫ brains (Qiao et al., 2007) , the scope of neuroinflammation in INCL has largely gone underappreciated. The severity of the immune cell activation and recruitment in the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ PPT1 Ϫ/Ϫ mice illustrates the need to further understand this pathogenic mechanism so that all aspects of CNS disease are properly targeted therapeutically in INCL.
Returning to the question, "are reactive astrocytes beneficial or deleterious in INCL?," this study investigated the role of attenuated astrocyte activation in a mouse model of chronic neurodegeneration using the GFAP Ϫ/Ϫ Vim Ϫ/Ϫ mice. To date, astrocyte activation has largely been studied in models of acute trauma or injury. Findings from those studies demonstrate a complex response of both positive and negative outcomes. Our data are consistent with these previous studies in that reactive astrocytes are protective in INCL. This study is of particular interest because, in contrast to most other models used to define reactive astrocytes, INCL is one of the few models where GFAP upregulation is a widespread phenomenon, glial scarring of small lesions or infarcts is absent, CNS disease is both chronic and progressive, and the disease-causing mechanism (i.e., PPT1 deficiency) remains present for the duration of life. Given this unique set of characteristics, these data help further the understanding of reactive astrocytes in yet another example of CNS disease. This has important implications not only for our understanding and treatment of INCL, but also for our understanding of the complicated relationship between intermediate filament upregulation, reactive astrocytes, and neurodegeneration in other chronic neurodegenerative disorders, like AD, PD, or ALS.
